Leukemia: Clinical Trials

1,354 trials for Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1354 completed. 1354 Phase 1, 403 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11354Completed 1354
Phase 2403Completed 403

Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia

Trials (filtered) newest first · largest first

All 1,354 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
14C-bleximenib, bleximenib - Acute Lymphoblastic Leukemia, Acute Leukemias
Phase 1CompletedJanssen Research & Development, LLC62025-11-182026-09-25
TGRX-678 Pharmacokinetic Mass Balance
[14C]TGRX-678 - Chronic Myeloid Leukemia
Phase 1CompletedShenzhen TargetRx Co., Ltd.62025-07-072025-09-04
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state - Acute Promyelocytic Leukemia (APL)
Phase 1CompletedSDK Therapeutics, Inc.122025-03-112025-11-18
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
JNJ-89853413 - Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms
Phase 1CompletedJanssen Research & Development, LLC642025-01-142026-11-03
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
Blinatumomab - B-precursor Acute Lymphoblastic Leukemia
Phase 1CompletedAmgen62025-01-082026-05-13
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL
Phase 1 / Phase 2CompletedNational Research Center for Hematology, Russia582024-11-262026-02-09
TGRX-678 Phase I Oral Pharmacokinetic Study
TGRX-678 - Chronic Myeloid Leukemia
Phase 1CompletedShenzhen TargetRx Co., Ltd.762024-11-242025-05-16
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CTX131 - T Cell Lymphoma, B Cell Lymphoma
Phase 1CompletedCRISPR Therapeutics122024-08-132026-11-05
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
ZE50-0134 or placebo, Rabeprazole 20 mg, Itraconazole (200 mg) - Healthy
Phase 1CompletedLomond Therapeutics Holdings, Inc.1042024-05-212025-12-05
Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)
Azacitidine, Onureg - Acute Myeloid Leukaemia
Phase 1CompletedHikma Pharmaceuticals LLC322024-05-022025-09-26
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1 / Phase 2CompletedChongqing Precision Biotech Co., Ltd52024-03-282026-08-05
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Treosulfan, Fludarabine - Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Phase 1Completedmedac GmbH202024-02-012026-05-20
A Study of PD5K3 in Healthy Adult Volunteers
PD5K3, Placebo, Pegaspargase - Lymphoblastic Leukemia, Acute, Lymphoblastic Lymphoma
Phase 1CompletedChongqing Peg-Bio Biopharm Co., Ltd.282023-11-272024-07-30
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase 1CompletedPrelude Therapeutics Incorporated862023-09-122026-01-26
Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia
CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine - AML, Adult, Minimal Residual Disease
Phase 1CompletedInstitute of Hematology & Blood Diseases Hospital, China22023-07-312026-02-11
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
BMF-500 - Acute Myeloid Leukemia
Phase 1CompletedBiomea Fusion Inc.352023-07-262026-09-23
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
WU-NK-101 - Acute Myeloid Leukemia
Phase 1CompletedAllotera Therapeutics92023-07-012025-09-30
LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML
LILRB4 STAR-T cells - Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia
Phase 1CompletedPeking University People's Hospital112023-05-252025-03-05
Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors
KT-253 - Myeloid Malignancies, Acute Lymphocytic Leukemia
Phase 1CompletedKymera Therapeutics, Inc.522023-05-152025-01-27
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Cobimetinib, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1CompletedCity of Hope Medical Center32023-04-282026-05-05

Showing 20 of 1354. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (636)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (444)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (434)  ·  Lymphoma, Non-Hodgkin (281)  ·  Myelodysplastic Syndromes (274)  ·  Lymphoma (241)  ·  Lymphoma, Mantle-Cell (227)  ·  Lymphoma, Follicular (226)  ·  Lymphoma, Large B-Cell, Diffuse (207)  ·  Lymphoma, B-Cell, Marginal Zone (200)  ·  Burkitt Lymphoma (188)  ·  Hodgkin Disease (184)  ·  Lymphoma, Large-Cell, Immunoblastic (150)  ·  Multiple Myeloma (144)

Broader conditions

Hemic and Lymphatic Diseases (1354)  ·  Neoplasms by Histologic Type (1350)  ·  Hematologic Diseases (1345)  ·  Neoplasms (1280)  ·  Immune System Diseases (831)  ·  Immunoproliferative Disorders (825)  ·  Lymphoproliferative Disorders (819)  ·  Lymphatic Diseases (814)  ·  Leukemia, Myeloid (757)  ·  Pathological Conditions, Signs and Symptoms (744)  ·  Pathologic Processes (743)  ·  Disease Attributes (736)  ·  Leukemia, Lymphoid (730)  ·  Chronic Disease (666)

Interventions

Cytarabine (163)  ·  Cyclophosphamide (101)  ·  fludarabine phosphate (94)  ·  Rituximab (76)  ·  Azacitidine (69)  ·  fludarabine (66)  ·  Filgrastim (63)  ·  Etoposide (58)  ·  Decitabine (52)  ·  Peripheral Blood Stem Cell Transplantation (52)  ·  Methotrexate (44)  ·  Lenalidomide (40)  ·  Mitoxantrone (40)  ·  venetoclax (39)  ·  Bortezomib (38)

Sponsors

National Cancer Institute (NCI) (141)  ·  M.D. Anderson Cancer Center (82)  ·  Fred Hutchinson Cancer Center (40)  ·  Memorial Sloan Kettering Cancer Center (26)  ·  Novartis Pharmaceuticals (24)  ·  Washington University School of Medicine (20)  ·  Dana-Farber Cancer Institute (18)  ·  Celgene (17)  ·  City of Hope Medical Center (17)  ·  Massachusetts General Hospital (16)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (15)  ·  Mayo Clinic (14)  ·  AbbVie (13)  ·  National Institutes of Health Clinical Center (CC) (13)  ·  Baylor College of Medicine (12)

Countries

United States (1085)  ·  Canada (92)  ·  France (88)  ·  Germany (85)  ·  United Kingdom (66)  ·  Australia (65)  ·  Italy (55)  ·  Spain (51)  ·  Japan (42)  ·  China (38)  ·  South Korea (34)  ·  Netherlands (29)  ·  Poland (22)  ·  Switzerland (17)  ·  Austria (15)

Top investigators

Jorge Cortes, MD (10)  ·  Brenda Sandmaier (6)  ·  Farhad Ravandi-Kashani, MD (6)

Results publications

PMID 34515338, PMID 32499241, PMID 34398557, PMID 34687939, PMID 37486616, PMID 39368878, PMID 16775234, PMID 19238148, PMID 19949018, PMID 20028764, PMID 20882050, PMID 21816833, PMID 22002018, PMID 23660685, PMID 23886836, PMID 24055823, PMID 25317870, PMID 25381051, PMID 26182309, PMID 26813675, PMID 26943915, PMID 27400247, PMID 27482888, PMID 28877686, PMID 31023700, PMID 31355467, PMID 33883258, PMID 33917201, PMID 34699069, PMID 34780125, PMID 35829925, PMID 38376944, PMID 41429239, PMID 10552943, PMID 10764422, PMID 11331327, PMID 11410496, PMID 11474661, PMID 11585760, PMID 11756154, PMID 11896112, PMID 12114413, PMID 12171484, PMID 12750167, PMID 14630685, PMID 14767498, PMID 15013589, PMID 15231574, PMID 15241836, PMID 15466934

NIH funding

P30CA015704 (18), U01CA070095 (17), P30CA006973 (16), U01CA076576 (15), P30CA016672 (13), P30CA033572 (11), 2015 (10), 2016 (10), P30CA016058 (10), U01CA062461 (10), U01CA062502 (8), U01CA062505 (8), U01CA069912 (8), U01CA097452 (8), 2009 (7)